FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380624062> ?p ?o ?g. }

• W4380624062 abstract "Abstract Background and Aims We aimed to investigate the characteristics and survival data of biopsy-proven primary focal segmental glomerulosclerosis (FSGS) in adult patients across Turkey. Method Patients with primary FSGS were included by retrospectively scanning the database of the Turkish Society of Nephrology Glomerular Diseases Study Group (TSN-GOLD). Demographic and laboratory data of the patients at baseline, sixth month, first year, and third year were recorded. Patients with secondary FSGS, missing data were excluded. Results The study included 1668 patients with primary FSGS who met the criteria. 1386 patients were included. The mean age of the patients was 41.16±13.88 years, and 712 patients (51.4%) were male. The total follow-up period from the biopsy date was 37.63±40.45 (IQR:1-249) months. The mean blood pressure of the patients, respectively; 130.43±17.63/81.47±10.85 mmHg, serum creatinine 1.29±1.28 mg/dl, e-GFR: 86.10±42.70 ml/min/1.73 m2, serum albumin: 3.41±0.92 g/dl and proteinuria amount was 4687±4658 g/day. Microscopic hematuria was detected in 40.2% of the patients. The rate of admission with nephrotic syndrome was .45.7%. In light microscopy, the mean glomeruli count was 17.36±10.58, with 3.32±4.08 global sclerosis and 0.08±065 glomeruli had segmental sclerosis. Mesangial proliferation was found in 53.1% of the patients and interstitial inflammation was found in 69.7% of the patients. Interestingly, the most common immunoglobulin staining was IgM (19.3%) in the immunofluorescent microscope. The rate of receiving immunosuppressive therapy was 36%. A positive correlation was found in terms of serum creatinine, albumin, and proteinuria in the 3-year follow-up (p&lt;0.001). In the univariate analysis, the group with e-GFR&lt;60 ml/min/1.73 m2 was older, hypertensive, uremic, anemic, had more interstitial fibrosis/tubular atrophy and less interstitial inflammation and mesangial proliferation (p&lt;0.001). In terms of quantitative proteinuria, Patients with proteinuria &gt;3.5 g/day were more hypertensive, hyperlipidemic, hypoalbuminemic and anemic (p&lt;0.05). Conclusion Our study presented important data on the status of patients with national primary FSGS. Approximately one-third of patients receive immunosuppressive therapy. The most important factors determining the prognosis of primary FSGS are the initial nephrotic proteinuria and the degree of renal function." @default.
• W4380624062 created "2023-06-15" @default.
• W4380624062 creator A5000865079 @default.
• W4380624062 creator A5002478763 @default.
• W4380624062 creator A5003132118 @default.
• W4380624062 creator A5010020998 @default.
• W4380624062 creator A5010763621 @default.
• W4380624062 creator A5011812164 @default.
• W4380624062 creator A5011933163 @default.
• W4380624062 creator A5013405328 @default.
• W4380624062 creator A5016119804 @default.
• W4380624062 creator A5016234312 @default.
• W4380624062 creator A5016489026 @default.
• W4380624062 creator A5019013419 @default.
• W4380624062 creator A5019357782 @default.
• W4380624062 creator A5025137049 @default.
• W4380624062 creator A5027574972 @default.
• W4380624062 creator A5027726050 @default.
• W4380624062 creator A5030857356 @default.
• W4380624062 creator A5033830295 @default.
• W4380624062 creator A5035825446 @default.
• W4380624062 creator A5037164918 @default.
• W4380624062 creator A5044597017 @default.
• W4380624062 creator A5047898288 @default.
• W4380624062 creator A5049168431 @default.
• W4380624062 creator A5052187627 @default.
• W4380624062 creator A5053376996 @default.
• W4380624062 creator A5055342508 @default.
• W4380624062 creator A5057735608 @default.
• W4380624062 creator A5063360767 @default.
• W4380624062 creator A5064198798 @default.
• W4380624062 creator A5067507723 @default.
• W4380624062 creator A5070495193 @default.
• W4380624062 creator A5071611970 @default.
• W4380624062 creator A5071840454 @default.
• W4380624062 creator A5076147925 @default.
• W4380624062 creator A5078483635 @default.
• W4380624062 creator A5078907038 @default.
• W4380624062 creator A5080242186 @default.
• W4380624062 creator A5080374214 @default.
• W4380624062 creator A5080656078 @default.
• W4380624062 creator A5081421684 @default.
• W4380624062 creator A5083058331 @default.
• W4380624062 creator A5089164006 @default.
• W4380624062 date "2023-06-01" @default.
• W4380624062 modified "2023-10-18" @default.
• W4380624062 title "#3476 CHARACTERISTICS AND SURVIVAL DATA OF PATIENTS WITH PRIMARY FOCAL SEGMENTAL SEGMENTAL GLOMERULOSCLEROSIS: TSN-GOLD MULTI-CENTER STUDY" @default.
• W4380624062 doi "https://doi.org/10.1093/ndt/gfad063c_3476" @default.
• W4380624062 hasPublicationYear "2023" @default.
• W4380624062 type Work @default.
• W4380624062 citedByCount "0" @default.
• W4380624062 crossrefType "journal-article" @default.
• W4380624062 hasAuthorship W4380624062A5000865079 @default.
• W4380624062 hasAuthorship W4380624062A5002478763 @default.
• W4380624062 hasAuthorship W4380624062A5003132118 @default.
• W4380624062 hasAuthorship W4380624062A5010020998 @default.
• W4380624062 hasAuthorship W4380624062A5010763621 @default.
• W4380624062 hasAuthorship W4380624062A5011812164 @default.
• W4380624062 hasAuthorship W4380624062A5011933163 @default.
• W4380624062 hasAuthorship W4380624062A5013405328 @default.
• W4380624062 hasAuthorship W4380624062A5016119804 @default.
• W4380624062 hasAuthorship W4380624062A5016234312 @default.
• W4380624062 hasAuthorship W4380624062A5016489026 @default.
• W4380624062 hasAuthorship W4380624062A5019013419 @default.
• W4380624062 hasAuthorship W4380624062A5019357782 @default.
• W4380624062 hasAuthorship W4380624062A5025137049 @default.
• W4380624062 hasAuthorship W4380624062A5027574972 @default.
• W4380624062 hasAuthorship W4380624062A5027726050 @default.
• W4380624062 hasAuthorship W4380624062A5030857356 @default.
• W4380624062 hasAuthorship W4380624062A5033830295 @default.
• W4380624062 hasAuthorship W4380624062A5035825446 @default.
• W4380624062 hasAuthorship W4380624062A5037164918 @default.
• W4380624062 hasAuthorship W4380624062A5044597017 @default.
• W4380624062 hasAuthorship W4380624062A5047898288 @default.
• W4380624062 hasAuthorship W4380624062A5049168431 @default.
• W4380624062 hasAuthorship W4380624062A5052187627 @default.
• W4380624062 hasAuthorship W4380624062A5053376996 @default.
• W4380624062 hasAuthorship W4380624062A5055342508 @default.
• W4380624062 hasAuthorship W4380624062A5057735608 @default.
• W4380624062 hasAuthorship W4380624062A5063360767 @default.
• W4380624062 hasAuthorship W4380624062A5064198798 @default.
• W4380624062 hasAuthorship W4380624062A5067507723 @default.
• W4380624062 hasAuthorship W4380624062A5070495193 @default.
• W4380624062 hasAuthorship W4380624062A5071611970 @default.
• W4380624062 hasAuthorship W4380624062A5071840454 @default.
• W4380624062 hasAuthorship W4380624062A5076147925 @default.
• W4380624062 hasAuthorship W4380624062A5078483635 @default.
• W4380624062 hasAuthorship W4380624062A5078907038 @default.
• W4380624062 hasAuthorship W4380624062A5080242186 @default.
• W4380624062 hasAuthorship W4380624062A5080374214 @default.
• W4380624062 hasAuthorship W4380624062A5080656078 @default.
• W4380624062 hasAuthorship W4380624062A5081421684 @default.
• W4380624062 hasAuthorship W4380624062A5083058331 @default.
• W4380624062 hasAuthorship W4380624062A5089164006 @default.
• W4380624062 hasBestOaLocation W43806240621 @default.
• W4380624062 hasConcept C126322002 @default.
• W4380624062 hasConcept C126894567 @default.
• W4380624062 hasConcept C142724271 @default.
• W4380624062 hasConcept C159641895 @default.
• W4380624062 hasConcept C2775934546 @default.

• next